Tegoprubart是一种新的肾移植药物,其肾功能与Tacrolimus相似,副作用较少,促使进入第三阶段试验。 Tegoprubart, a new kidney transplant drug, showed similar kidney function to tacrolimus with fewer side effects, prompting advancement to Phase 3 trials.

Eledon制药公司报告说,在2025年Kidney周,Tegoprubart(一种新的免疫抑制剂)的试验结果为积极的阶段2BESTOW试验结果。 Eledon Pharmaceuticals reported positive Phase 2 BESTOW trial results for tegoprubart, a new immunosuppressant, at Kidney Week 2025. 在127名肾移植病人中,Tegoprubart表现出了类似的肾功能——平均12个月的eGFR为69毫升/min/1.73平方米,同时大大降低了副作用,如新发糖尿病、颤抖、高血压和心脏衰竭,而与塔克罗利姆相比。 In 127 kidney transplant patients, tegoprubart showed comparable kidney function—average 12-month eGFR of 69 mL/min/1.73 m²—while significantly reducing side effects like new-onset diabetes, tremor, hypertension, and heart failure compared to tacrolimus. 它还降低了延迟的移植功能和透析时间,造成类似的感染和严重不良事件率,没有PTLD或PML病例。 It also lowered delayed graft function and dialysis duration, with similar infection and serious adverse event rates, and no cases of PTLD or PML. 尽管急性排斥程度略高,但留在Tegoprubart的患者的肾功能仍然较好。 Though acute rejection was slightly higher, kidney function remained better in those staying on tegoprubart. 成果支持将tegoprubart推进到第三阶段试验,作为目前标准疗法的更安全的替代方法。 Results support advancing tegoprubart to Phase 3 trials as a safer alternative to current standard therapy.